Effect of HER-2/neu over-expression on prognosis in gastric cancer: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 6, 2011, Pages 1417-1423

  Wang, Shuyi ^a   Zheng, Gang ^a   Chen, Liangdong ^a   Xiong, Bin ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Gastric neoplasia; Gene; HER2 neu; Meta analysis; Prognosis; Relative risk

Indexed keywords

EID: 84863294022     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Alderson P, Creen S, Higgins JPT, et al (2004) Cochrane reviewer's handbook4.2.2 (update MSTVH2004). In: Cochrane Library. Issue 1.Chichester: Wiley: 102-153.
2. Allgayer H, Babic R, Gruetzner KU, et al (2000). c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol, 18, 2201-9.
3. Bang YJ, Cutsem EV, Feyereislova A, et al (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet, 376, 687-97.
4. Barros-Silva JD, Leitao D, Afonso L, et al (2009). Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer, 100, 487-93.
5. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
6. Chae S, Lee A, Lee JH (2011). The effectiveness of the new (7th) UICC N classification in the prognosis evaluation of gastric cancer patients: a comparative study between the 5th/6th and 7th UICC N classification. Gastric Cancer, Published online:01 March.
7. Cunningham D, Allum WH, Stenning SP, et al (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Eng J Med, 355, 11-22.
8. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
9. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
10. Garcia I, Vizoso F, Martin A, et al (2003). Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol, 10, 234-41.
11. Gong ZJ, Luo EZ, Lu Q et al (1996) Clinical significance of c-erbB-2: oncoprotein expression in stomach. Chin J Oncol, 18, 299-301 (in Chinese).
12. Grabsch H, Sivakumar S, Gray S et al (2010) HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cellular Oncol, 32, 57-65.
13. Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 19, 1523-29.
14. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
15. Hilton DA, West KP (1992). c-erbB-2 oncogene product expression and prognosis in gastric carcinoma. J Clin Pathol, 45, 454-6.
16. Hofmann M, O. Stoss, Shi D, et al (2008).Assessment of a HER2 scoring system for gastric cancer:results from a validation study. Histopathology, 52, 797-805.
17. Jain S, Filipe I, Gullick WJ, et al (1991). c-erB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. Int J Cancer, 48, 668-671.
18. Kamangar F, Dores GM, Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 24, 2137-50.
19. Kubicka S, Claas C, Staab S, et al (2002). p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer relation to histological subtypes, helicobacter pylori infection, and prognosis. Dig Dis Sci, 47, 114-21.
20. Lee KE, Lee HJ, Kim YH et al (2003). Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol, 33, 173-97.
21. Li Ning et al (1994). Overexpression of c-erbB-2 proto-oncogene product in gastric carcinoma in relation to prognosis. Chin J Clin Oncol, 21, 831-3 (in Chinese).
22. Lin C, Zhu XC (1998). The expression of p53 gene and c-erbB-2 gene in gastric cancer. Chin J Gen Surg, 7, 337-40 (in Chinese).
23. McShane LM, Altman DG, Sauerbrei W, et al (2005). Reporting recommendations for tumour marker prognostic studies. Br J Cancer, 93, 387-91.
24. Nakajima M, Sawada H, et al (1999). The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer, 85, 1894-902.
25. Paoletti X, K. Oba, et al (2010). Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA, 303, 1729-32.
26. Park DII, Yun JW, Park JH et al (2006). HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci, 51, 1371-9.
27. Parmar MKB, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.
28. Pauletti G, Godolphin W, Press MF, Slamon DJ (1996). Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene, 13, 63-72.
29. Pham B, Klassen TP, Lawson ML, Moher D (2005). Language of publication restrictions in systematic reviews gave different results depending on whether the intervention was conventional or complementary. J Clin Epidemiol, 58, 769-76.
30. Pinto-de-Sousa J, David L, Almeida R et al (2002). c-erbB-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol, 10, 247-56.
31. Sasano H, Date F, Imatani A et al (1993) Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol, 24, 584-9.
32. Seidal T, Balaton AJ, Battifora H (2001). Interpretation and quantification of immunostains. Am J Surg Pathol, 25, 1204-7.
33. Im SA, Lee KE, Nam E et al (2005). Potential prognostic significance of p185HER2 overexpression with loss of PTEN expression in gastric carcinomas. Tumori, 91, 513-21.
34. Shao CK, Zhu ZG, et al (2000) The expression of p53, c-erbB-2, EGFR, nm23 and E-cadherin and their prognostic value in gastric carcinoma. Cancer, 19, 666-70 (in Chinese).
35. Stroup DF, Berlin JA, Morton SC, et al (2000). Meta -analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Obervational Studies in Epidemiology (MOOSE) group. JAMA, 283, 2008-12.
36. Van Cutsem E, Kang Y, Chung H, et al (2009). Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in firstline human epidermal growth factor receptor 2-positive advanced gastric cancer. J Clin Oncol, 27(15S), LBA4509.
37. Vita FD, Giuliani F, Silvestris N et al (2010). Human epidermal growth factor receptor2(HER2) in gastric cancer: a new therapeutic target. Cancer Treatment Reviews, 36S3, S11-S15.
38. Yasui W, Oue N, Aung PP, Matsumura S, et al (2005). Molecular-pathological prognostic factors of gastric cancer:a review. Gastric Cancer, 8, 86-94.
39. Yonemura Y, Ninomiya I, Yamaguchi A et al (1991) Evaluation of Immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res, 51, 1034-8.
40. Yu GZ, Chen Y, Wang JJ (2009) Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol, 135, 1331-9.